Malignant Thoracic Neoplasm

We now report responses to the MET inhibitors crizotinib and cabozantinib in four patients with stage IV lung adenocarcinomas harboring mutations leading to MET exon 14 skipping.

PMID 25971939 · Paik et al., 2015 · Open in CIViC

A single patient with a MET c.3028G>A (splice donor site of exon 14) mutation exhibited clinical sensitivity to the c-Met inhibitor crizotinib. Exon 14 skipping was detected using qRT-PCR. Response to… (full text at CIViC)

PMID 26729443 · Awad et al., 2016 · Open in CIViC

A 68-year old woman (former smoker: 24 pack-years) was diagnosed with advanced lung adenocarcinoma. Genomic profiling yielded MET exon 14 skipping mutation (c.e14 1 G>A), PIK3CA mutation (c.1624 G>A),… (full text at CIViC)

PMID 26791794 · Jorge et al., 2015 · Open in CIViC

A 59-year old woman was diagnosed with lung adenocarcinoma after a 15 cm right upper lobe lung mass was found with multiple lymph nodes and pleural nodules. Next-generation sequencing revealed a MET e… (full text at CIViC)

PMID 30553716 · Rotow et al., 2019 · Open in CIViC

A 67-year old Asian woman (non-smoker) was diagnosed with stage IV adenocarcinoma with pleural and rib disease. The patient underwent a lobectomy and then received carboplatin/paclitaxel/bevacizumab. … (full text at CIViC)

PMID 30762593 · Wang et al., 2019 · Open in CIViC

Case report of a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation and major response to crizotinib.

PMID 26845194 · Shea et al., 2016 · Open in CIViC

In this case Report, a 67-year old female patient with a lung adenocarcinoma displaying a MET exon 14 donor splice site mutation (D1028N) detected using next generation sequencing. Within 5 weeks of c… (full text at CIViC)

PMID 26892698 · Mahjoubi et al., 2016 · Open in CIViC

A 60-year old woman (non-smoker) was diagnosed with stage IV lung adenocarcinoma after finding a 5.7 x 5.1 cm left pleural-based mass with multiple invasions. The patient was put on carboplatin and pe… (full text at CIViC)

PMID 27987579 · Dong et al., 2016 · Open in CIViC

A 77-year-old Caucasian woman (previous smoker) was diagnosed with stage IV adenocarcinoma with pleural disease. She received six cycles of carboplatin/pemetrexed which was followed by pemetrexed main… (full text at CIViC)

PMID 30762593 · Wang et al., 2019 · Open in CIViC

A 62-year old Asian man (non-smoker) was diagnosed with stage IV adenocarcinoma with pleural metastases. He received pemetrexed, docetaxel, nivolumab, and gemcitabine. Genetic testing revealed MET exo… (full text at CIViC)

PMID 30762593 · Wang et al., 2019 · Open in CIViC

In a never-smoking metastatic lung adenocarcinoma patient harboring a MET splice site mutation (c.2887-18_2887-7del12) treated with crizotinib monotherapy, was associated with a response as evident … (full text at CIViC)

PMID 25769807 · Jenkins et al., 2015 · Open in CIViC

A 77-year old woman was diagnosed with lung adenocarcinoma harboring a MET exon 14 skipping mutation after PET-CT scans showed a right upper lobe mass, right hilar enlarged lymph nodes, and multiple b… (full text at CIViC)

PMID 33530219 · Qin et al., 2021 · Open in CIViC

A 49-year old female (non-smoker) presented with a 3.8 x 2.9 cm mass that was diagnosed as Stage IIIA lung adenocarcinoma. Genetic testing revealed a MET exon 14 skipping mutation, to which the patien… (full text at CIViC)

PMID 36052259 · Fu et al., 2022 · Open in CIViC

In this open-label phase 2 trial, MET inhibitor tepotinib was administered to patients with non-small cell lung cancer and MET exon 14 skipping mutation found in either liquid and/or tissue biopsy. A … (full text at CIViC)

PMID 32469185 · Paik et al., 2020 · Open in CIViC

In the VISION phase 2 trial (NCT02864992), 313 patients with advanced, metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations were treated with 500 mg/kg tepotinib daily. In t… (full text at CIViC)

PMID 37270698 · Mazieres et al., 2023 · Open in CIViC

In a interim analysis of Phase II trial for MET exon 14 skipping NSCLC, 34 patients received MEK selective inhibitor tepotinib. 9/15 (60.0%) evaluable patients had a confirmed PR and 3 (20.0%) had SD.… (full text at CIViC)

Open in CIViC

A 56-year old male (smoker: 50 pack-years) was diagnosed with stage IIIA lung adenocarcinoma. Patient underwent four cycles of cisplatin and pemetrexed and maintenance therapy with pemetrexed but was … (full text at CIViC)

PMID 33387444 · Tanaka et al., 2021 · Open in CIViC

An 84-year old man (smoker: 62-pack-years) was diagnosed with stage IVB non-small-cell lung cancer (NSCLC) and was started on carboplatin and nab-paclitaxel. After the tumor progressed, the patient wa… (full text at CIViC)

PMID 35383870 · Tanaka et al., 2022 · Open in CIViC

A 57-year female (non-smoker) was diagnosed with lung adenocarcinoma via pleural fluid cytology. After multigene testing revealed MET exon 14 skipping mutation, the patient was switched from cisplatin… (full text at CIViC)

PMID 36810936 · Ikeo et al., 2023 · Open in CIViC

A 75-year old woman presented with lung adenocarcinoma (stage IVA) to which next-generation sequencing revealed METex14del. The patient was put on crizotinib (500 mg/day) and showed partial response f… (full text at CIViC)

PMID 33533182 · Takamori et al., 2021 · Open in CIViC

A 60-year old male (smoker: 38 pack-years presented with stage IIB lung adenocarcinoma. After receiving an upper lobectomy, the left lobar lymph node was pathologically positive and received cisplati… (full text at CIViC)

PMID 37228358 · Onodera et al., 2023 · Open in CIViC

A 65-year old male (non-smoker) presented with advanced sarcomatoid non-small-cell lung cancer harboring a MET exon 14 skipping mutation with elevated PDL1 levels (tumor proportion score of 80%). Afte… (full text at CIViC)

PMID 35871685 · Gonugunta et al., 2022 · Open in CIViC

A 58-year old male (non-smoker/non-drinker) was diagnosed with metastatic adenocarcinoma with sarcomatoid components. A tissue sample revealed a MET exon 14 skipping mutation and the patient was treat… (full text at CIViC)

PMID 35110965 · Gu et al., 2022 · Open in CIViC

An 83-year old male (smoker) was diagnosed with adenocarcinoma of right upper lung. Next-generation sequencing (NGS) analysis found MET exon 14 skipping mutation and MET C526F mutation and the patient… (full text at CIViC)

PMID 31055074 · Jin et al., 2019 · Open in CIViC

A 70-year old male (former smoker: 50 pack-years) was diagnosed with stage Ib lung adenocarcinoma. Next-generation sequencing showed a MET exon 14 skipping mutation, confirmed later with RNA analysis.… (full text at CIViC)

PMID 34994615 · Pruis et al., 2021 · Open in CIViC

A 61-year old male (non-smoker) was diagnosed with sarcomatoid non-small-cell lung cancer (CK+, TTF1+, and vimentin+). Genomic profiling showed two MET alterations that showed exon 14 skipping mutatio… (full text at CIViC)

PMID 26709483 · Lee et al., 2015 · Open in CIViC

38 patients with locally advanced or metastatic non-small-cell lung cancer were divided into two groups, Part A had c-MET overexpression and Part B had MET exon 14 skipping mutation. Part A was given … (full text at CIViC)

PMID 37041472 · Hu et al., 2023 · Open in CIViC

A 67-year old Asian female (non-smoker) diagnosed with stage IV metastatic lung adenocarcinoma and also presented with superior vena cava syndrome and weight loss. Ultrasound-guided biopsy of lymph no… (full text at CIViC)

PMID 27666659 · Ou et al., 2017 · Open in CIViC

A 71-year old male (non-smoker) was diagnosed with stage IV lung adenocarcinoma. Genomic profiling of a lung cavity showed MET exon 14 skipping mutation and the patient began crizotinib therapy. Treat… (full text at CIViC)

PMID 28629543 · Schrock et al., 2017 · Open in CIViC

Analysis of 32 patients with lung neoplasms from the University of Chicago Medical Center. Results yielded high c-MET levels in 100% of all non-small-cell lung cancer samples (n=23) and 89% of all cel… (full text at CIViC)

PMID 15735036 · Ma et al., 2005 · Open in CIViC

Patient small-cell lung cancer cells with c-MET juxtamembrane mutations (R988C or T1010I) were shown to have increased tyrosine phosphorylated cellular proteins such as paxillin, a focal adhesion cyto… (full text at CIViC)

PMID 14559814 · Ma et al., 2003 · Open in CIViC

A 69-year old male (50 year history of smoking) was diagnosed with stage IIIC lung adenocarcinoma after a 13.2 x 8.8 x 9 cm mass with multiple lymph node metastases were found in a CT scan. Next-gener… (full text at CIViC)

PMID 29381967 · Tan et al., 2017 · Open in CIViC

A homozygous splice site point mutation at the donor site of Met Exon 14 (G>T at +1 position; Figure 1A, and Figure S1a) was identified in the H596 lung cancer cell line. RT-PCR of RNA demonstrated sk… (full text at CIViC)

PMID 16397241 · Kong-Beltran et al., 2006 · Open in CIViC

A 72-year old man (non-smoker) was diagnosed with lung adenocarcinoma and developed multiple recurring brain and lung metastases. Systemic chemotherapy was administered, and genomic analysis of the su… (full text at CIViC)

PMID 34695875 · Kunimasa et al., 2021 · Open in CIViC

A 83-year old woman presented with sarcomatoid squamous cell carcinoma. Next-generation sequencing revealed a MET exon 14 skipping mutation (c.3028+3A>G) and the patient was treated with crizotinib (2… (full text at CIViC)

PMID 36147925 · Sun et al., 2022 · Open in CIViC

In one patient with metastastic lung adenocarcinoma harboring a c-Cbl binding site alteration (Y1021H) deomonstrated radiological response to crizotinib and a PFS of 10.6 months.

PMID 31809977 · Wiesweg et al., 2020 · Open in CIViC

A 61-year old female (non-smoker) was diagnosed with stage IIIb adenocarcinoma of the left lung. Next-generation sequencing of the peripheral blood revealed MET Y1003S mutation. The patient was treate… (full text at CIViC)

PMID 30885356 · Miao et al., 2019 · Open in CIViC

MIR21 expression was assessed in 58 NSCLC patient samples by real-time PCR. There was a significant association between MIR21 expression and platinum sensitivity (p=0.007). MIR21 expression was signif… (full text at CIViC)

PMID 22237007 · Gao et al., 2012 · Open in CIViC

MIR21 expression was assessed in 58 NSCLC patient samples by real-time PCR and a significant association between MIR21 expression and platinum sensitivity was found (p=0.007). To directly test the rol… (full text at CIViC)

PMID 22237007 · Gao et al., 2012 · Open in CIViC

In a retrospective cohort of metastatic lung adenocarcinoma from the BATTLE-2 trial (n = 72), patients with CDKN2A and MTAP co-underexpression tumors (n = 26; representative for 9p21 loss) demonstrate… (full text at CIViC)

PMID 35379845 · Alhalabi et al., 2022 · Open in CIViC

A preclinical study to evaluate the efficacy of targeting the overexpressed CHEK1 cell cycle chekpoint kinase, including both miRNA and Prexasertib-induced inhibition. Both in vitro and in vivo, Prexa… (full text at CIViC)

PMID 28490518 · Sen et al., 2017 · Open in CIViC

In a cohort of 178 patients with lung squamous cell carcinoma from The Cancer Genome Atlas, high neoantigen burden was significantly associated with improved disease-free survival compared with low ne… (full text at CIViC)

PMID 30824826 · Chae et al., 2019 · Open in CIViC

Approximately 2% of NSCLCs had RASA1 truncating mutations, and this alteration was statistically, but not completely, mutually exclusive with known activating EGFR (p=0.02) and KRAS (p=0.02) mutations… (full text at CIViC)

PMID 29127119 · Hayashi et al., 2018 · Open in CIViC

In a phase 2 trial, patients with squamous cell lung carcinoma harboring NFE2L2 mutation were treated with oral TORC1/2 inhibitor TAK228. ORR 25% (1 PR, 3 SD, 0 PD).

Open in CIViC